Global Malignant Mesothelioma Market Research Report 2023

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

The global Malignant Mesothelioma market was valued at US$ 475.3 million in 2022 and is anticipated to reach US$ 674.2 million by 2029, witnessing a CAGR of 6.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma.

The Malignant Mesothelioma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Malignant Mesothelioma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Malignant Mesothelioma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Malignant Mesothelioma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Oral

1.2.3 Parenteral

1.3 Market by Application

1.3.1 Global Malignant Mesothelioma Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Oncology Centers

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Malignant Mesothelioma Market Perspective (2018-2029)

2.2 Malignant Mesothelioma Growth Trends by Region

2.2.1 Global Malignant Mesothelioma Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Malignant Mesothelioma Historic Market Size by Region (2018-2023)

2.2.3 Malignant Mesothelioma Forecasted Market Size by Region (2024-2029)

2.3 Malignant Mesothelioma Market Dynamics

2.3.1 Malignant Mesothelioma Industry Trends

2.3.2 Malignant Mesothelioma Market Drivers

2.3.3 Malignant Mesothelioma Market Challenges

2.3.4 Malignant Mesothelioma Market Restraints

3.1 Global Top Malignant Mesothelioma Players by Revenue

3.1.1 Global Top Malignant Mesothelioma Players by Revenue (2018-2023)

3.1.2 Global Malignant Mesothelioma Revenue Market Share by Players (2018-2023)

3.2 Global Malignant Mesothelioma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Malignant Mesothelioma Revenue

3.4 Global Malignant Mesothelioma Market Concentration Ratio

3.4.1 Global Malignant Mesothelioma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Revenue in 2022

3.5 Malignant Mesothelioma Key Players Head office and Area Served

3.6 Key Players Malignant Mesothelioma Product Solution and Service

3.7 Date of Enter into Malignant Mesothelioma Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Malignant Mesothelioma Historic Market Size by Type (2018-2023)

4.2 Global Malignant Mesothelioma Forecasted Market Size by Type (2024-2029)

5.1 Global Malignant Mesothelioma Historic Market Size by Application (2018-2023)

5.2 Global Malignant Mesothelioma Forecasted Market Size by Application (2024-2029)

6.1 North America Malignant Mesothelioma Market Size (2018-2029)

6.2 North America Malignant Mesothelioma Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Malignant Mesothelioma Market Size by Country (2018-2023)

6.4 North America Malignant Mesothelioma Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Malignant Mesothelioma Market Size (2018-2029)

7.2 Europe Malignant Mesothelioma Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Malignant Mesothelioma Market Size by Country (2018-2023)

7.4 Europe Malignant Mesothelioma Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Malignant Mesothelioma Market Size (2018-2029)

8.2 Asia-Pacific Malignant Mesothelioma Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Malignant Mesothelioma Market Size by Region (2018-2023)

8.4 Asia-Pacific Malignant Mesothelioma Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Malignant Mesothelioma Market Size (2018-2029)

9.2 Latin America Malignant Mesothelioma Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Malignant Mesothelioma Market Size by Country (2018-2023)

9.4 Latin America Malignant Mesothelioma Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Malignant Mesothelioma Market Size (2018-2029)

10.2 Middle East & Africa Malignant Mesothelioma Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Malignant Mesothelioma Market Size by Country (2018-2023)

10.4 Middle East & Africa Malignant Mesothelioma Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 AstraZeneca

11.1.1 AstraZeneca Company Detail

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Malignant Mesothelioma Introduction

11.1.4 AstraZeneca Revenue in Malignant Mesothelioma Business (2018-2023)

11.1.5 AstraZeneca Recent Development

11.2 Bristol-Myers Squibb

11.2.1 Bristol-Myers Squibb Company Detail

11.2.2 Bristol-Myers Squibb Business Overview

11.2.3 Bristol-Myers Squibb Malignant Mesothelioma Introduction

11.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2018-2023)

11.2.5 Bristol-Myers Squibb Recent Development

11.3 Roche

11.3.1 Roche Company Detail

11.3.2 Roche Business Overview

11.3.3 Roche Malignant Mesothelioma Introduction

11.3.4 Roche Revenue in Malignant Mesothelioma Business (2018-2023)

11.3.5 Roche Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck Malignant Mesothelioma Introduction

11.4.4 Merck Revenue in Malignant Mesothelioma Business (2018-2023)

11.4.5 Merck Recent Development

11.5 Novartis

11.5.1 Novartis Company Detail

11.5.2 Novartis Business Overview

11.5.3 Novartis Malignant Mesothelioma Introduction

11.5.4 Novartis Revenue in Malignant Mesothelioma Business (2018-2023)

11.5.5 Novartis Recent Development

11.6 Pfizer

11.6.1 Pfizer Company Detail

11.6.2 Pfizer Business Overview

11.6.3 Pfizer Malignant Mesothelioma Introduction

11.6.4 Pfizer Revenue in Malignant Mesothelioma Business (2018-2023)

11.6.5 Pfizer Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Detail

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Malignant Mesothelioma Introduction

11.7.4 Sanofi Revenue in Malignant Mesothelioma Business (2018-2023)

11.7.5 Sanofi Recent Development

11.8 Eli Lilly

11.8.1 Eli Lilly Company Detail

11.8.2 Eli Lilly Business Overview

11.8.3 Eli Lilly Malignant Mesothelioma Introduction

11.8.4 Eli Lilly Revenue in Malignant Mesothelioma Business (2018-2023)

11.8.5 Eli Lilly Recent Development

11.9 Teva Pharmaceuticals

11.9.1 Teva Pharmaceuticals Company Detail

11.9.2 Teva Pharmaceuticals Business Overview

11.9.3 Teva Pharmaceuticals Malignant Mesothelioma Introduction

11.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)

11.9.5 Teva Pharmaceuticals Recent Development

11.10 Boehringer Ingelheim GmbH

11.10.1 Boehringer Ingelheim GmbH Company Detail

11.10.2 Boehringer Ingelheim GmbH Business Overview

11.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Introduction

11.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2018-2023)

11.10.5 Boehringer Ingelheim GmbH Recent Development

11.11 Mylan

11.11.1 Mylan Company Detail

11.11.2 Mylan Business Overview

11.11.3 Mylan Malignant Mesothelioma Introduction

11.11.4 Mylan Revenue in Malignant Mesothelioma Business (2018-2023)

11.11.5 Mylan Recent Development

11.12 Fresenius Kabi

11.12.1 Fresenius Kabi Company Detail

11.12.2 Fresenius Kabi Business Overview

11.12.3 Fresenius Kabi Malignant Mesothelioma Introduction

11.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Business (2018-2023)

11.12.5 Fresenius Kabi Recent Development

11.13 Sun Pharmaceuticals

11.13.1 Sun Pharmaceuticals Company Detail

11.13.2 Sun Pharmaceuticals Business Overview

11.13.3 Sun Pharmaceuticals Malignant Mesothelioma Introduction

11.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)

11.13.5 Sun Pharmaceuticals Recent Development

11.14 Corden Pharma

11.14.1 Corden Pharma Company Detail

11.14.2 Corden Pharma Business Overview

11.14.3 Corden Pharma Malignant Mesothelioma Introduction

11.14.4 Corden Pharma Revenue in Malignant Mesothelioma Business (2018-2023)

11.14.5 Corden Pharma Recent Development

11.15 Concordia International

11.15.1 Concordia International Company Detail

11.15.2 Concordia International Business Overview

11.15.3 Concordia International Malignant Mesothelioma Introduction

11.15.4 Concordia International Revenue in Malignant Mesothelioma Business (2018-2023)

11.15.5 Concordia International Recent Development

11.16 Kyowa Hakko Kirin

11.16.1 Kyowa Hakko Kirin Company Detail

11.16.2 Kyowa Hakko Kirin Business Overview

11.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Introduction

11.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2018-2023)

11.16.5 Kyowa Hakko Kirin Recent Development

11.17 Polaris Pharmaceuticals

11.17.1 Polaris Pharmaceuticals Company Detail

11.17.2 Polaris Pharmaceuticals Business Overview

11.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Introduction

11.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023)

11.17.5 Polaris Pharmaceuticals Recent Development

11.18 MolMed

11.18.1 MolMed Company Detail

11.18.2 MolMed Business Overview

11.18.3 MolMed Malignant Mesothelioma Introduction

11.18.4 MolMed Revenue in Malignant Mesothelioma Business (2018-2023)

11.18.5 MolMed Recent Development

11.19 Ono Pharmaceutical

11.19.1 Ono Pharmaceutical Company Detail

11.19.2 Ono Pharmaceutical Business Overview

11.19.3 Ono Pharmaceutical Malignant Mesothelioma Introduction

11.19.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023)

11.19.5 Ono Pharmaceutical Recent Development

11.20 Nichi-Iko Pharmaceutical

11.20.1 Nichi-Iko Pharmaceutical Company Detail

11.20.2 Nichi-Iko Pharmaceutical Business Overview

11.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Introduction

11.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023)

11.20.5 Nichi-Iko Pharmaceutical Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Malignant Mesothelioma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Oral

    Table 3. Key Players of Parenteral

    Table 4. Global Malignant Mesothelioma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Malignant Mesothelioma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Malignant Mesothelioma Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Malignant Mesothelioma Market Share by Region (2018-2023)

    Table 8. Global Malignant Mesothelioma Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Malignant Mesothelioma Market Share by Region (2024-2029)

    Table 10. Malignant Mesothelioma Market Trends

    Table 11. Malignant Mesothelioma Market Drivers

    Table 12. Malignant Mesothelioma Market Challenges

    Table 13. Malignant Mesothelioma Market Restraints

    Table 14. Global Malignant Mesothelioma Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Malignant Mesothelioma Market Share by Players (2018-2023)

    Table 16. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2022)

    Table 17. Ranking of Global Top Malignant Mesothelioma Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Malignant Mesothelioma Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Malignant Mesothelioma Product Solution and Service

    Table 21. Date of Enter into Malignant Mesothelioma Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Malignant Mesothelioma Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Malignant Mesothelioma Revenue Market Share by Type (2018-2023)

    Table 25. Global Malignant Mesothelioma Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Malignant Mesothelioma Revenue Market Share by Type (2024-2029)

    Table 27. Global Malignant Mesothelioma Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Malignant Mesothelioma Revenue Market Share by Application (2018-2023)

    Table 29. Global Malignant Mesothelioma Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Malignant Mesothelioma Revenue Market Share by Application (2024-2029)

    Table 31. North America Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Malignant Mesothelioma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Malignant Mesothelioma Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Malignant Mesothelioma Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Malignant Mesothelioma Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Malignant Mesothelioma Market Size by Country (2024-2029) & (US$ Million)

    Table 46. AstraZeneca Company Detail

    Table 47. AstraZeneca Business Overview

    Table 48. AstraZeneca Malignant Mesothelioma Product

    Table 49. AstraZeneca Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 50. AstraZeneca Recent Development

    Table 51. Bristol-Myers Squibb Company Detail

    Table 52. Bristol-Myers Squibb Business Overview

    Table 53. Bristol-Myers Squibb Malignant Mesothelioma Product

    Table 54. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 55. Bristol-Myers Squibb Recent Development

    Table 56. Roche Company Detail

    Table 57. Roche Business Overview

    Table 58. Roche Malignant Mesothelioma Product

    Table 59. Roche Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 60. Roche Recent Development

    Table 61. Merck Company Detail

    Table 62. Merck Business Overview

    Table 63. Merck Malignant Mesothelioma Product

    Table 64. Merck Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 65. Merck Recent Development

    Table 66. Novartis Company Detail

    Table 67. Novartis Business Overview

    Table 68. Novartis Malignant Mesothelioma Product

    Table 69. Novartis Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 70. Novartis Recent Development

    Table 71. Pfizer Company Detail

    Table 72. Pfizer Business Overview

    Table 73. Pfizer Malignant Mesothelioma Product

    Table 74. Pfizer Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 75. Pfizer Recent Development

    Table 76. Sanofi Company Detail

    Table 77. Sanofi Business Overview

    Table 78. Sanofi Malignant Mesothelioma Product

    Table 79. Sanofi Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 80. Sanofi Recent Development

    Table 81. Eli Lilly Company Detail

    Table 82. Eli Lilly Business Overview

    Table 83. Eli Lilly Malignant Mesothelioma Product

    Table 84. Eli Lilly Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 85. Eli Lilly Recent Development

    Table 86. Teva Pharmaceuticals Company Detail

    Table 87. Teva Pharmaceuticals Business Overview

    Table 88. Teva Pharmaceuticals Malignant Mesothelioma Product

    Table 89. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 90. Teva Pharmaceuticals Recent Development

    Table 91. Boehringer Ingelheim GmbH Company Detail

    Table 92. Boehringer Ingelheim GmbH Business Overview

    Table 93. Boehringer Ingelheim GmbH Malignant Mesothelioma Product

    Table 94. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 95. Boehringer Ingelheim GmbH Recent Development

    Table 96. Mylan Company Detail

    Table 97. Mylan Business Overview

    Table 98. Mylan Malignant Mesothelioma Product

    Table 99. Mylan Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 100. Mylan Recent Development

    Table 101. Fresenius Kabi Company Detail

    Table 102. Fresenius Kabi Business Overview

    Table 103. Fresenius Kabi Malignant Mesothelioma Product

    Table 104. Fresenius Kabi Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 105. Fresenius Kabi Recent Development

    Table 106. Sun Pharmaceuticals Company Detail

    Table 107. Sun Pharmaceuticals Business Overview

    Table 108. Sun Pharmaceuticals Malignant Mesothelioma Product

    Table 109. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 110. Sun Pharmaceuticals Recent Development

    Table 111. Corden Pharma Company Detail

    Table 112. Corden Pharma Business Overview

    Table 113. Corden Pharma Malignant Mesothelioma Product

    Table 114. Corden Pharma Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 115. Corden Pharma Recent Development

    Table 116. Concordia International Company Detail

    Table 117. Concordia International Business Overview

    Table 118. Concordia International Malignant Mesothelioma Product

    Table 119. Concordia International Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 120. Concordia International Recent Development

    Table 121. Kyowa Hakko Kirin Company Detail

    Table 122. Kyowa Hakko Kirin Business Overview

    Table 123. Kyowa Hakko Kirin Malignant Mesothelioma Product

    Table 124. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 125. Kyowa Hakko Kirin Recent Development

    Table 126. Polaris Pharmaceuticals Company Detail

    Table 127. Polaris Pharmaceuticals Business Overview

    Table 128. Polaris Pharmaceuticals Malignant Mesothelioma Product

    Table 129. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 130. Polaris Pharmaceuticals Recent Development

    Table 131. MolMed Company Detail

    Table 132. MolMed Business Overview

    Table 133. MolMed Malignant Mesothelioma Product

    Table 134. MolMed Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 135. MolMed Recent Development

    Table 136. Ono Pharmaceutical Company Detail

    Table 137. Ono Pharmaceutical Business Overview

    Table 138. Ono Pharmaceutical Malignant Mesothelioma Product

    Table 139. Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 140. Ono Pharmaceutical Recent Development

    Table 141. Nichi-Iko Pharmaceutical Company Detail

    Table 142. Nichi-Iko Pharmaceutical Business Overview

    Table 143. Nichi-Iko Pharmaceutical Malignant Mesothelioma Product

    Table 144. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2018-2023) & (US$ Million)

    Table 145. Nichi-Iko Pharmaceutical Recent Development

    Table 146. Research Programs/Design for This Report

    Table 147. Key Data Information from Secondary Sources

    Table 148. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Malignant Mesothelioma Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Malignant Mesothelioma Market Share by Type: 2022 VS 2029

    Figure 3. Oral Features

    Figure 4. Parenteral Features

    Figure 5. Global Malignant Mesothelioma Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Malignant Mesothelioma Market Share by Application: 2022 VS 2029

    Figure 7. Hospital Pharmacies Case Studies

    Figure 8. Retail Pharmacies Case Studies

    Figure 9. Oncology Centers Case Studies

    Figure 10. Others Case Studies

    Figure 11. Malignant Mesothelioma Report Years Considered

    Figure 12. Global Malignant Mesothelioma Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Malignant Mesothelioma Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Malignant Mesothelioma Market Share by Region: 2022 VS 2029

    Figure 15. Global Malignant Mesothelioma Market Share by Players in 2022

    Figure 16. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Revenue in 2022

    Figure 18. North America Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Malignant Mesothelioma Market Share by Country (2018-2029)

    Figure 20. United States Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Malignant Mesothelioma Market Share by Country (2018-2029)

    Figure 24. Germany Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Malignant Mesothelioma Market Share by Region (2018-2029)

    Figure 32. China Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Malignant Mesothelioma Market Share by Country (2018-2029)

    Figure 40. Mexico Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Malignant Mesothelioma Market Share by Country (2018-2029)

    Figure 44. Turkey Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Malignant Mesothelioma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. AstraZeneca Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 48. Roche Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 49. Merck Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 50. Novartis Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 51. Pfizer Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 52. Sanofi Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 53. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 54. Teva Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 55. Boehringer Ingelheim GmbH Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 56. Mylan Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 57. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 58. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 59. Corden Pharma Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 60. Concordia International Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 61. Kyowa Hakko Kirin Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 62. Polaris Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 63. MolMed Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 64. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 65. Nichi-Iko Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2018-2023)

    Figure 66. Bottom-up and Top-down Approaches for This Report

    Figure 67. Data Triangulation

    Figure 68. Key Executives Interviewed